Stephen J Hoffman
CIK 1190418 · Chief Executive Officer · last filed 2026-06-24
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
GNCA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
1850 GATEWAY DRIVE, SUITE 175
SAN MATEO, CA 94404
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TLPH | Director | 13,959 | $1.10 | $15.4K | $0 | 3 | 2026-06-24 |
| TALPHERA, INC. (ACRX) Delisted | Director | 146,015 | $0.86 | $125.6K | $0 | 8 | 2023-12-13 |
| Dicerna Pharmaceuticals Inc (DRNA) Delisted | Director | 312,000 | $38.22 | $11.92M | $3.00M | 9 | 2021-12-29 |
| Whitehawk Therapeutics, Inc. (ARPO) Delisted | Chief Executive Officer | 131 | $33.00 | $4.3K | $64.1K | 3 | 2019-05-16 |
| GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Director | 249,052 | $0.00 | $149 | $8.79M | 4 | 2016-06-07 |
| ALLOS THERAPEUTICS INC (ALTH) Delisted | Director | 0 | — | — | -$2.45M | 12 | 2012-09-05 |
| Sirtris Pharmaceuticals, Inc. (SIRT) Delisted | Director | 1,376,190 | — | — | $0 | 1 | 2007-05-31 |
Recent Filings · Page 5 of 5
42 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2007-06-21 | ALLOS THERAPEUTICS INC (ALTH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2007-05-31 | Sirtris Pharmaceuticals, Inc. (SIRT) Delisted | Conv (C) | +1,846,145 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.